The Novartis scandal represents a significant chapter in the ongoing discourse surrounding ethics
in the pharmaceutical sector, particularly in relation to allegations of corruption and bribery. This
analysis explores the intricacies of the scandal, the penalties imposed by U.S. authorities, the
conflicts arising from the legal frameworks of Greece and the United States and the implications
these differences have an effect on the protection status of whistleblowers.